GlaxoSmithKline's (GSK) hopes of a return to growth for its embattled respiratory division in 2016 have been knocked back after the failure of a large-scale trial of new drug Breo/Relvar.

GSK plc's stock downgraded from “Buy” to “Hold” due to litigation risks, disappointing RSV vaccine sales, and competitive pressures in the HIV space. Despite strong cash flow, GSK's Zantac ...

GSK GSK stock has declined 20.2% in the past three months compared with a decrease of 12.3% for the industry. The stock has also underperformed the sector and the S&P 500 index, as seen in the ...

Big pharma company GSK and UK AI-biotech Relation Therapeutics have entered into two strategic collaborations to identify and validate new therapeutic targets for osteoarthritis and fibrotic diseases.

GSK has handed over $45 million upfront to fellow London-based firm Relation to help the pharma identify new targets for fibrotic diseases and osteoarthritis. The two-stranded collaboration will ...

Ma­chine learn­ing and AI have sparked a trans­for­ma­tion in drug dis­cov­ery, but crack­ing the bi­ol­o­gy is still para­mount.

GSK is now looking to start a phase 3 trial in the first-line setting shortly, Abdullah said. The DREAMM-10 study will once again pit Blenrep against Darzalex, this time as part of front-line ...

近日，葛兰素史克（GSK）与映恩生物就一项ADC药物(DB-1324)，达成独家授权协议。根据协议，GSK将获得该药全球（不包括中国大陆、香港地区和澳门 ...

LONDON — A blood cancer treatment from GSK helped patients live longer in a pivotal trial, a significant finding as the once-withdrawn drug mounts a comeback. In the study, a treatment ...

The Blenrep comeback continues for GSK. The blood cancer treatment, which was once pulled off the market, was found to help patients live longer in a Phase 3 clinical trial, the results of which were ...